Loading...

FHTX FOGHORN THERAPEUTICS INC US FDA Inspections 8-K Filing

FGHR

FHTX

FOGHORN THERAPEUTICS INC

(FHTX)

2023 8-K

Show Summary

Show Summary

Financial Statements

Clinical Trials

Investor Presentation

Stock Sale Amendment

Financial Results

Investor Presentation

Audit Committee Notice

Preliminary Results

Director Resignation

Product Discontinuation

Financial Results

Trial Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Public Offering

Financial Results Announcement

Appointment of CFO

Conference Call and Webcast

Financial Results Announcement

Appointment of CFO

Press Release and Investor ...

Departure of Chief Financia...

Financial Results Announcement

Termination of Agreement

Management Changes

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Update on FHD-609 Program

Financial Results and Bylaw...

Press Release and Investor ...

External Links:

Foghorn Therapeutics announced the first patient dosed in its Phase 1 combination study of FHD-286 for relapsed and/or refractory acute myelogenous leukemia (AML).

AI Assistant

FOGHORN THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.